Cancer treatment today is increasingly planned around the biology of the tumour and the patient's overall health. For many patients, treatment discussions now include options beyond chemotherapy, such as targeted therapy and immunotherapy. These treatments work in different ways and are selected according to the cancer type, stage and biomarker test results.
When comparing targeted therapy vs immunotherapy, it is important to understand how each treatment works and when it may be recommended. Targeted therapy acts on specific cancer-related genes, proteins or pathways, while immunotherapy helps the immune system recognise and attack cancer cells. Biomarker testing, treatment goals, possible side effects and overall health all play important roles in deciding which option is suitable.
Modern oncology has moved beyond a one-size-fits-all approach. Treatment today is shaped by the tumour's biology, the patient's overall health, and the cancer's stage. Both immunotherapy and targeted therapy are part of this shift toward personalized cancer care. Patients often compare the two when reviewing treatment options. The choice is rarely either-or it depends on the cancer type, the presence of specific biomarkers, and the broader treatment plan. Access to a comprehensive cancer hospital in Mumbai supports a careful evaluation of both pathways.
Targeted therapy uses drugs that act on specific molecules within or on cancer cells. These molecules, including proteins, genes or signalling pathways, drive tumour growth. By blocking them, targeted drugs slow or stop the cancer while sparing most healthy cells. This precision is what sets targeted therapy apart from conventional chemotherapy.
Key features include:
Immunotherapy works in a different way. Instead of attacking the tumour directly, it activates the patient's own immune system to recognise and destroy cancer cells. The immune system sometimes fails to identify cancer because tumours can hide or suppress immune responses. Immunotherapy removes these brakes and restores the body's ability to fight the disease.
Common features include:
Although both are forms of precision cancer care, they differ in several important dimensions. The table below summarises the difference between targeted therapy and immunotherapy at a glance.
Targeted therapy and immunotherapy can offer important benefits in modern cancer care when used for suitable patients. Key benefits may include:
The benefits of these treatments vary from patient to patient. A specialist oncology review helps decide whether targeted therapy, immunotherapy or another treatment approach is suitable.
Cancer treatment decisions need careful review of the tumour type, stage, biomarker results and the patient’s overall health. At Sir H. N. Reliance Foundation Hospital, patients can receive evaluation from medical oncology, pathology, radiology and other cancer care teams. For those looking for a cancer hospital in Mumbai, the hospital supports personalised treatment planning through advanced diagnostics, molecular profiling and multidisciplinary tumour board review. This helps doctors assess whether targeted therapy, immunotherapy, chemotherapy, radiation therapy or a combination approach may be suitable.
When comparing targeted therapy vs immunotherapy, it is important to remember that both treatments are designed for different clinical situations. The right choice depends on the cancer type, biomarker results, and the patient's overall health. A detailed evaluation helps doctors select the treatment that is most appropriate for each patient's needs.
When choosing a cancer hospital in Mumbai, patients should look for experienced oncology teams, advanced diagnostic services and access to personalised cancer treatments. This approach supports informed treatment decisions and coordinated care throughout the treatment journey.
Duration varies widely. Targeted therapy is often continued as long as the drug works and side effects remain manageable. Immunotherapy may be given for a defined course, typically up to two years, or until a meaningful response is achieved. Your oncologist will tailor the schedule to your response and tolerance.
Yes, in many cancers, either can be a first-line option. The decision depends on tumour biology and biomarker testing. For some cancers, such as EGFR-mutated lung cancer or PD-L1-high lung cancer, these treatments are now the preferred first choice over chemotherapy.
Many patients do continue working, particularly with oral targeted therapies. Energy levels and side effects vary, so workload adjustments may be needed. Your treating team can advise based on your specific regimen and how you respond.
Regular monitoring is essential. Blood tests, scans, and clinical review are typically scheduled every few weeks during active treatment. The frequency depends on the drug, side-effect profile, and how the cancer is responding.
Yes, switching is possible and sometimes necessary. If a targeted therapy stops working due to resistance, immunotherapy may be considered, or vice versa. Switching decisions are guided by repeat biomarker testing, disease progression, and how the patient has tolerated previous treatment.
Disclaimer:
This article is for general information only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified oncologist or healthcare professional regarding any medical condition or treatment decision.
Medically Reviewed By: Dr. Sewanti Limaye, Director — Department of Medical Oncology, Sir H. N. Reliance Foundation Hospital